Skip to main content

17 March 2022 by OXGENE

Webinar: Cell & Gene Therapy Vector Regulatory Testing

WuXi Advanced Therapies Virology Operations: Cell & Gene Therapy Vector Regulatory Testing

About this event

Cell and gene therapy regulatory testing is a constantly evolving discipline as the field matures and data becomes more refined. Virology Operations at WuXi Advanced Therapies is able to provide testing for a variety of products ranging from small non-enveloped AAV vectors to large enveloped lentiviral vectors.

Our testing is performed as quickly as testing parameters permit without sacrificing the quality and integrity of results. Our panel of testing satisfies all ICH parameters delivering results on the quantity, stability, potency, identity, appearance, purity and safety of viral vector products.

We are evolving with the field to optimize our assays such as replication competence testing and infectious titer assays for scalability; we accommodate needs as products progress from early R&D and IND phase through clinical trials with the goal of sustaining the testing requirements and supporting through commercial release.



Andreas Solomos, PhD

Director, Virology Operations,

WuXi Advanced Therapies

Andreas Solomos has focused his research on CNS immunity and viral pathogenesis and is fascinated by all host-pathogen interactions. He completed his doctorate at Drexel College of Medicine in microbiology and immunology. His post-doctoral training at Trinity College Dublin focused on cancer immunology collaborating with industry. He is trained in a wide variety of cellular and molecular techniques and has experience in training individual students, groups of individuals, and teaching at a collegiate level. He is currently leading the Virology Operations group at WuXi Advanced Therapies performing safety and regulatory testing on biologic drug products and cell and gene therapy vectors.


This webinar is hosted by BioProcess International and you can sign up here: